QRVO
4
-23
BMY
50
5
EW
29
-5
MLM
51
-3
SYK
37
-3
KMX
60
-4
STZ
55
-2
UNM
65
-3
GS
48
-2
PNR
32
-19
XRX
28
-3
MCK
75
-2
JPM
63
-6
CFG
60
-8
CVX
58
-5
LEG
29
-2
BK
65
-4
JBHT
35
-3
PFE
35
-2
CSCO
58
-2
QRVO
4
-23
BMY
50
5
EW
29
-5
MLM
51
-3
SYK
37
-3
KMX
60
-4
STZ
55
-2
UNM
65
-3
GS
48
-2
PNR
32
-19
XRX
28
-3
MCK
75
-2
JPM
63
-6
CFG
60
-8
CVX
58
-5
LEG
29
-2
BK
65
-4
JBHT
35
-3
PFE
35
-2
CSCO
58
-2
Financhill
Back

Madrigal Pharmaceuticals 10K Form

Buy
51

MDGL
Madrigal Pharmaceuticals

Last Price:
$327.73
Seasonality Move:
9.46%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive MDGL News And Ratings

See the #1 stock for the next 7 days that we like better than MDGL

MDGL Financial Statistics

Sales & Book Value

Annual Sales: $180.1M
Cash Flow: $-104.7M
Price / Cash Flow: 0
Annual Sales: $34.28
Price / Book: 9.6

Profitability

EPS (TTM): -22.11000
Net Income (TTM): $-465.9M
Gross Margin: $173.9M
Return on Equity: -63.91%
Return on Assets: -47.17%

Madrigal Pharmaceuticals Earnings Forecast

Key Madrigal Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 8 years for MDGL is 96.54%.
  • The Selling, General & Administrative Expenses for MDGL have been equal to 241.52% of Gross Profit Margin.
  • The Research & Development expenses have been 131.41% of Revenue.
  • The Net Earning history of MDGL is -258.64% of Total Revenues.
  • Per Share Earnings over the last 24 years have been positive in 8 years.

Madrigal Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: MDGL
CUSIP: 558868
Website: madrigalpharma.com

Debt

Debt-to-Equity Ratio: 0.16
Current Ratio: 6.1
Quick Ratio: 5.79

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 188.67

MDGL Technical Analysis vs Fundamental Analysis

Buy
51
Madrigal Pharmaceuticals (MDGL) is a Buy

Is Madrigal Pharmaceuticals a Buy or a Sell?